Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
11.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-11.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
-1.2
-
Book Value
$--
-
EPS
$-0.9
-
Face value
--
-
Shares outstanding
2,653,480
6 Years Aggregate
CFO
$-76.49 Mln
EBITDA
$-99.88 Mln
Net Profit
$-111.55 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kiromic Biopharma Inc (KRBP)
| -95.5 | -63.4 | -96.8 | -98.8 | -86.5 | -- | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Kiromic Biopharma Inc (KRBP)
| 3.4 | -84.0 | -88.2 | -81.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kiromic Biopharma Inc (KRBP)
|
0.0 | 0.2 | 0.0 | -26.9 | -- | 247.8 | -- | 11.5 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Kiromic Biopharma Inc (KRBP)
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's... lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
CEO & Director
Mr. Pietro Bersani CPA, J.D.
-
Chief Financial Officer
Mr. Brian Hungerford CPA, CGMA
-
Headquarters
Houston, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kiromic Biopharma Inc (KRBP)
What is the current share price of Kiromic Biopharma Inc (KRBP) Today?
The share price of Kiromic Biopharma Inc (KRBP) is $0.04 (NASDAQ) as of 13-Jun-2025 09:30 EDT. Kiromic Biopharma Inc (KRBP) has given a return of -86.53% in the last 3 years.
What is the current PB & PE ratio of Kiromic Biopharma Inc (KRBP)?
Since, TTM earnings of Kiromic Biopharma Inc (KRBP) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-0.95 |
-2.04 |
2023 |
-1.35 |
-3.14 |
2022 |
0.00 |
-0.02 |
2021 |
-0.92 |
0.86 |
2020 |
-3.23 |
5.47 |
What is the 52 Week High and Low of Kiromic Biopharma Inc (KRBP)?
The 52-week high and low of Kiromic Biopharma Inc (KRBP) are Rs -- and Rs -- as of 06-Sep-2026.
What is the market cap of Kiromic Biopharma Inc (KRBP)?
Kiromic Biopharma Inc (KRBP) has a market capitalisation of $ 0 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kiromic Biopharma Inc (KRBP)?
Before investing in Kiromic Biopharma Inc (KRBP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.